By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise.  Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide).  It is the first once-a-week medication for T2DM in the market.…

By: Ebey P. Soman – With clearly established roles for pharmacists, compounding is recognized and upheld as a core foundation of the pharmacy profession.   It allows pharmacists to provide unique and tailored medication regimens for their patients.  The U.S. Food and Drug Administration (FDA) thought otherwise when the agency sued Franck’s Lab, Inc., a Florida-based…

By: Neal Shah – Part I:              Preface. Part II:             Brief review of cardiac electrophysiology. Part III:           Ivabradine as a novel If blocker for the use of stable angina. Part IV:           On the horizon: trimetazidine. – PREFACE When viewed anatomically, the heart may seem like a simple organ.  However, the electrophysiological aspects of the heart are…

By: Mahdieh Danesh Yazdi, with special thanks to Dr. Tomasz Jodlowski – Drug shortages have plagued health care institutions in recent years; they present a serious problem to health care delivery on a national scale. In 2004, there were 58 drug shortages; now, in 2011, this number has increased to 198. Due to limited access…